CRSP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CRISPR Therapeutics AG (CRSP) is not a strong buy for a beginner, long-term investor at the moment. While the company has potential due to its innovative pipeline and clinical updates, the technical indicators, insider selling, and recent financial performance suggest caution. The stock may be worth monitoring for future entry points, but it is not an ideal buy right now.
The technical indicators suggest a bearish trend. The MACD is below zero and negatively contracting, RSI is neutral at 40.968, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The current price of $47.72 is near the pivot level of $47.64, with resistance at $49.576 and support at $45.703.
Analysts have raised price targets recently, with Piper Sandler setting a target of $110 and Citi at $80, reflecting optimism about the company's pipeline and clinical updates.
The company raised $585.2 million through a convertible note offering, strengthening its cash position to $2.56 billion.
Insiders are selling heavily, with a 476.16% increase in selling activity over the last month.
The company's Q4 financials showed a significant revenue drop of -97.58% YoY, and net income remains negative at -$130.6 million.
Technical indicators are bearish, and the stock is trading below key moving averages.
In Q4 2025, revenue dropped significantly by -97.58% YoY to $864,000. Net income improved but remains negative at -$130.6 million, up 250.07% YoY. EPS also improved to -1.37, up 211.36% YoY. While gross margin is at 100%, the revenue decline and ongoing losses are concerning.
Analysts are mixed but slightly optimistic. Piper Sandler raised the price target to $110 with an Overweight rating, while Citi and Chardan also raised targets to $80 and $76, respectively, with Buy ratings. However, Morgan Stanley maintains an Underweight rating with a target of $33, and JPMorgan lowered its target to $67 while keeping an Overweight rating.
